- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02633982
GENERAL;GENeral Practitioners and Embolism pRevention in NVAF Patients Treated With RivAroxaban:reaL-life Evidence (GENeRAL)
Registry Study on the Effectiveness of Rivaroxaban in Patients With Non-valvular Atrial Fibrillation Managed by General Practitioners(GENERAL Study)
In atrial fibrillation patients,anticoagulant therapy with warfarin has an excellent stroke preventive. Meantime,Warfarin may also increase the risk of hemorrhagic events. Considering this,warfarin is a drug which puts a great burden on patients and medical providers.
With the population aging, the number of non-valvular atrial fibrillation patients is increasing, and a necessity that not only specialist but also general practitioners. Anticoagulant therapy with warfarin is not easy for general practitioners and is not commonly used among general practioners. In such circumstances, Rivaroxaban,a new oral direct factor Xa inhibitor,has become available. Rivaroxaban is administrated once a day and exert an anti- coagulant effect soon after administration. It hardly reacts with foods or other drugs and therefore does not require regular monitoring. GENERAL study is to investigate the effectiveness of stroke and systemic embolism in non-valvular atrial fibrillation patients when it is prescribed by general practioners in real life settings.
연구 개요
상태
정황
연구 유형
등록 (예상)
연락처 및 위치
연구 연락처
- 이름: Saburo Saito
- 전화번호: +81-6-6872-0010
- 이메일: general@jcvrf.jp
연구 장소
-
-
Osaka
-
Suita, Osaka, 일본, 565-8565
- 모병
- Japan Cardiovascular Research Foundation
-
연락하다:
- Hisao Ogawa
- 전화번호: 2231 +81-6-6833-5012
- 이메일: ogawah@ncvc.go.jp
-
수석 연구원:
- Hisao Ogawa, M.D.
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Non-valvular atrial fibrillation patient who are prescribed Rivaroxaban by General practitioners
Exclusion Criteria:
- Patients are contraindicated for rivaroxaban
- Patients judged as inappropriate for this study by investigators
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: 보병대
- 시간 관점: 유망한
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Composite of symptomatic stroke (ischemic/hemorrhagic) and systemic embolism
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Major bleeding events (adapted ISTH standard)
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Non-major bleeding events(without Major Bleeding complications)
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Composite of symptomatic stroke(ischemic or hemorrhagic),systemic embolism,myocardial infarction/unstable angina pectoris and cardiovascular death
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Symptomatic stroke (ischemic or hemorrhagic)
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Symptomatic ischemic stroke
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Symptomatic hemorrhagic stroke
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Systemic embolism
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Acute myocardial infarction/unstable angina pectoris
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Cardiovascular death
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Deep vein thrombosis/pulmonary thromboembolism
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Transient ischemic attack
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Percutaneous coronary intervention /coronary artery bypass grafting
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
All cause death
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Comparison of primary outcome (composite of symptomatic stroke(ischemic/hemorrhagic) and systemic embolism) rate and Major Bleeding complications (adapted ISTH standard)rate between EXPAND study and FUSHIMI AF registry
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Adverse Event excluding hemorrhagic events
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Patients adherence related with stroke or systemic embolism
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Correlation with CHADS2 score or other risk factors and outcome events in Japanese patients who administered Rivaroxaban
기간: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
심방세동에 대한 임상 시험
-
Assistance Publique - Hôpitaux de Paris아직 모집하지 않음과도한 Supraventricular Ectopies 또는 Short Atrial Runs(ESVEA)
-
University of Pennsylvania빼는전형적인 심방 조동 | Atrial Flutter의 향후 개발 위험 요소미국